Semaglutide oral - Novo Nordisk
Alternative Names: GLP-1-SNAC; NN 6535; NN 9932; NN-9924; NNC0113-0217; OG-217SC; Rybelsus; SemagutideLatest Information Update: 17 May 2024
At a glance
- Originator Novo Nordisk
- Class Antidementias; Antihyperglycaemics; Glucagon-like peptides; Hepatoprotectants; Obesity therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Phase III Alzheimer's disease; Obesity
Most Recent Events
- 30 Apr 2024 Novo Nordisk completes a phase I pharmacokinetics trial (In volunteers) in Canada (PO) (NCT06097390)
- 18 Apr 2024 Novo Nordisk completes a phase I trial in Healthy volunteers in Germany (PO) (NCT05996874) (EudraCT2022-002848-52)
- 29 Mar 2024 Novo Nordisk completes a phase I trial in Healthy volunteers in Canada and USA (PO) (NCT05784402)